VNRXVolitionRX Ltd

VolitionRx Limited Schedules First Quarter 2026 Earnings Conference Call and Business Update VolitionRx Limited Schedules First Quarter 2026 Earnings Conference Call and Business Update PR Newswire...

VolitionRx Announces Acceptance of Compliance Plan by NYSE American VolitionRx Announces Acceptance of Compliance Plan by NYSE American PR Newswire HENDERSON, Nev., April 23, 2026 HENDERSON, Nev...

VolitionRx Limited Announces Full Fiscal Year 2025 Financial Results and Business Update VolitionRx Limited Announces Full Fiscal Year 2025 Financial Results and Business Update PR Newswire...

VolitionRx Secures EUR 2.0 Million of Non-Dilutive Funding from Regional Government Agencies in Belgium VolitionRx Secures EUR 2.0 Million of Non-Dilutive Funding from Regional Government Agencies in...

Volition Announces Mayo Clinic Study Demonstrates Nu.Q Concentrations are Elevated in Trauma Patients Volition Announces Mayo Clinic Study Demonstrates Nu.Q Concentrations are Elevated in Trauma...

VolitionRx Limited Schedules Full Fiscal Year 2025 Earnings Conference Call and Business Update VolitionRx Limited Schedules Full Fiscal Year 2025 Earnings Conference Call and Business Update PR...

VolitionRx Limited (NYSE:VNRX) unveiled promising new data that could reshape the landscape of early cancer detection, reporting over 95% sensitivity in identifying stage I and II cancers using its proprietary Capture-Seq liquid biopsy technology.

The company said it has developed a new liquid biopsy method, and in a blinded validation cohort, it achieved over 95% sensitivity for stage I & II cancers with 95% specificity.

Volition Announces Detection of Over 95% of Early-Stage Cancers Volition Announces Detection of Over 95% of Early-Stage Cancers PR Newswire HENDERSON, Nev., March 25, 2026 Blinded validation cohort...